Today (1/7) Gemini Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted GEM103 treatment of dry age-related macular degeneration (AMD) for Fast Track designation. Gemini Therapeutics is a clinical stage precision medicine company based in Cambridge, MA. Jason Meyenburg, CEO of Gemini Therapeutics, stated, “We are pleased that the FDA has granted Fast Track designation to GEM103, which has the potential to be an important therapeutic option for patients with dry AMD and CFH loss-of- function gene variants. The FDA’s recognition of the existing unmet need in this patient population and this decision underscores the potential of GEM103 and its unique mechanism of action to treat this large population of AMD patients.”

Read more here.

More on: